Close

Form 8-K SEQUENOM INC For: May 04

May 5, 2016 6:04 AM EDT


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________

Form 8-K
____________________

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2016

SEQUENOM, INC.
(Exact name of registrant as specified in its charter)

Delaware
 
000-29101
 
77-0365889
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)

3595 John Hopkins Court
San Diego, California, 92121
(Address of principal executive offices, including zip code)
(858) 202-9000
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 2.02
Results of Operations and Financial Condition.

On May 4, 2016, we issued a press release announcing our financial results for the quarter ended March 31, 2016. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless we expressly set forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits
 
99.1
Press Release dated May 4, 2016

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
 
 
 
SEQUENOM, INC.
 
 
 
Date: May 4, 2016
 
By:
 
/s/ Jeffrey D. Linton
 
 
Name:
 
Jeffrey D. Linton
 
 
Title:
 
Senior Vice President, General Counsel and Secretary



 
 
Exhibit 99.1
FOR IMMEDIATE RELEASE
 
Sequenom Contacts:
Paul Goodson
Senior Director, Investor Relations and Corporate Communications
Sequenom, Inc.
858-202-9427

SEQUENOM, INC. REPORTS FIRST QUARTER 2016 RESULTS

SAN DIEGO, Calif. - May 4, 2016 - Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today reported total revenues of $27.6 million, total accessioned units of 46,400, and a net loss of $13.4 million, or $0.11 per basic and diluted share, for the first quarter of 2016.

“During the quarter, we executed on a number of key initiatives designed to return Sequenom to sustainable growth, resulting in quarter over quarter growth in our unit volume,” said Dirk van den Boom, Ph.D., President and CEO of Sequenom. “Overall, we made meaningful progress toward achieving our goal of becoming financially self-sustaining while solidifying our position as a leader in reproductive health.”

Operational Updates

To date in 2016, Sequenom and Sequenom Laboratories made significant progress on several key corporate objectives:

Total tests accessioned in the first quarter of 2016 reflect growth of 10% in test volume compared to the fourth quarter of 2015. Sequenom Laboratories’ total noninvasive prenatal test (NIPT) accessions in the first quarter of 2016 were up 3,900 units sequentially from the fourth quarter of 2015, for growth of 11%.

Completed the consolidation of Sequenom Laboratories’ North Carolina laboratory location into the San Diego laboratory location;

Enhanced San Diego laboratory productivity and restructured other key functions, consistent with the annualized cost reduction goal of greater than $20 million before the end of 2016;

Negotiated in-network contracts with Anthem Blue Cross and Blue Shield Health Plans for 11 states. Sequenom Laboratories has coverage for over 200 million commercial lives and 46 million lives under Medicaid programs;

Filed a writ of certiorari asking the U.S. Supreme Court to decide if the claims of Sequenom’s ‘540 patent are directed to patent-eligible subject matter;

Launched Sequenom Laboratories’ testing portfolio into the average risk pregnancy market and optimized its sales approach to better serve the obstetrician channel; and

Introduced a multi-faceted physician and patient customer experience program that seeks to provide a best-in-class experience at every step of the customer journey.


1


First Quarter 2016 Results

First quarter 2016 revenues of $27.6 million declined 27% from $37.8 million in the first quarter of 2015. Revenues and unit volumes in the first quarter of 2016 were lower than the first quarter of 2015, primarily reflecting the conversion of certain laboratory customers to licensee status under the Pooled Patents Agreement, and a smaller amount available to collect during the first quarter of 2016 for testing services performed in prior periods. This latter factor reflects the improvement in the timeliness of Sequenom Laboratories collections as a result of additional payor contracts. These changes resulted in approximately $10 million in net revenue reduction for the first quarter of 2016 compared to the first quarter of 2015.

Total patient samples accessioned decreased by 12% to 46,400 patient samples during the first quarter of 2016, compared to the prior year’s first quarter. Approximately 41,200 of those patient samples accessioned were for NIPT, including the MaterniT® 21 PLUS, VisibiliT and MaterniT® GENOME laboratory-developed tests, which is a 9% decrease in testing volume compared to the first quarter of 2015. The decrease in tests accessioned was driven by the conversions of laboratory customers to licensee status, as described above, partially offset by the increase in tests accessioned for patients in the average risk pregnancy market.

The total volume of tests from Sequenom’s core business increased by 7% over the first quarter of 2015, largely as a result of Sequenom Laboratories’ entry into the average risk pregnancy market. In this press release, “core business” refers to Sequenom’s revenue and unit volume excluding the effect of the conversion of certain laboratory customers to licensee status in 2015. Notably, the volume of NIPT tests in Sequenom’s core business, which includes average risk pregnancies, increased by 14% for the first quarter of 2016 over the first quarter of 2015.

License revenue was $2.2 million in the first quarter of 2016, compared to $2.1 million for the first quarter of 2015, and $2.3 million in the fourth quarter of 2015. Sequenom continues to expect a total of $10 million in license fee revenue for 2016.

Total cost of revenues decreased to $16.8 million for the first quarter of 2016, compared to $19.3 million for the prior year period. Cost of revenues decreased primarily due to the decrease in test volumes as a result of the conversion of certain laboratory customers to licensee status.

Gross margin for the first quarter of 2016 was 39% compared to gross margin of 49% for the first quarter of 2015. The effect of laboratory customers who converted to licensee status, costs associated with Sequenom Laboratories’ laboratory consolidation and restructuring, the impact of entering the average risk pregnancy market and increased MaterniT GENOME volume largely drove the decrease. Incremental costs related to the laboratory consolidation reduced gross margin for the first quarter of 2016 by 3%. Sequenom continues to expect gross margin to increase for the remaining quarters of 2016.

Total operating expenses for the first quarter of 2016 were $22.1 million, compared to $23.0 million for the first quarter of 2015. Total operating expenses for the first quarter of 2016 were up only slightly from total operating expenses of $21.9 million for the fourth quarter of 2015, due to the costs associated with Sequenom Laboratories’ laboratory consolidation and other restructuring activities, which offset the benefit of reduced spending for research and development and general and administrative activities.

Operating loss for the first quarter of 2016 was $11.4 million, compared to operating income of $16.5 million for the same period in 2015. Operating and net income for the first quarter of 2015 included a $21.0 million gain on the Pooled Patents Agreement with Illumina. Net loss for the first quarter of 2016 was $13.4 million or $0.11 per basic and diluted share, as compared to net income of $14.3 million, or $0.11 per diluted share, and $0.12 per basic share for the same period in 2015.

Cash burn for the first quarter of 2016 was $10.4 million, compared to $9.4 million in the same period of 2015 and $4.7 million in the fourth quarter of 2015. Cash burn increased in the first quarter of 2016 primarily due to reduced revenue collected for testing services performed in prior periods and delays in collections related to the launch of tests into the average risk pregnancy market. Cash burn in the first quarter also included semi-annual interest payments on Sequenom’s convertible debt.

Unrecorded accounts receivable for tests performed and recognized on a cash basis are estimated to be $16 million to $18 million as of March 31, 2016 , the same as the estimate as of December 31, 2015.

As of March 31, 2016, cash, cash equivalents, and marketable securities totaled $66.1 million.


2


Non-GAAP Financial Measures

“GAAP” refers to financial information presented in accordance with generally accepted accounting principles in the United States. To supplement the condensed consolidated financial statements and discussion presented on a GAAP basis, this press release includes non-GAAP financial measures with respect to the quarter ended March 31, 2016. Management uses non-GAAP financial measures because it believes that a cash flow metric incorporating cash used in operations and certain other uses of cash are important to understand the cash requirements of the business. The Company reported cash burn as a non-GAAP financial measure. This non-GAAP financial measure is not in accordance with or an alternative to GAAP.

Management uses cash burn to evaluate performance compared to forecasts. Cash burn is calculated as the sum of net cash used in operating activities, purchases of property, equipment and leasehold improvements, and payments on long-term obligations. The reconciliations of cash used by operating activities, the GAAP measure most directly comparable to cash burn, is provided on the attached schedule.

Conference Call Information

A conference call hosted by Dr. Dirk van den Boom, President and CEO of Sequenom, and other members of senior management, will take place on Wednesday, May 4, 2016, at 5:00 p.m. ET (2:00 p.m. PT) and will be webcast live on the Sequenom website.

Call participants should dial 877-883-0383 (U.S. / Canada) or 412-902-6506 (other countries). Please use code 4043466. A telephonic replay will be available through June 3, 2016 by dialing 877-344-7529 (US toll free), 855-669-9658 (Canada toll free), or 412-317-0088 (international toll), and entering the conference number 10085264.

The conference call webcast is also accessible through the “Investors” section of the Sequenom website at http://sequenom.investorroom.com/webcasts

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing company dedicated to women’s health through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information. For more information, visit www.sequenom.com.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT® 21 PLUS, NextView®, SensiGene® and VisibiliT these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit www.laboratories.sequenom.com and follow @SequenomLabs.

SEQUENOM®, HerediT®, MaterniT® GENOME, MaterniT® 21 PLUS, NextView®, SensiGene®, VisibiliT and Sequenom Laboratories are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding initiatives designed to return Sequenom to sustainable growth, Sequenom’s goal of becoming financially self-sustaining, solidifying Sequenom Laboratories’ position as a leader in reproductive health and a multi-faceted physician and patient customer experience program that seeks to provide a best-in-class experience at every step of the customer journey. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Sequenom’s filings with the Securities and Exchange Commission, including without limitation Sequenom’s most recent Annual Report on Form 10-K, Sequenom’s most recent Quarterly Reports on Form 10-Q, Sequenom’s most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Sequenom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

3


SEQUENOM, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(Unaudited)
(In thousands, except per share information)
 
 
 
Three Months Ended
 
March 31, 2016
 
March 31, 2015
Revenues:
 
 
 
Diagnostic services, net
$
25,410

 
$
35,703

License
2,160

 
2,102

Total revenues
27,570

 
37,805

Costs and expenses:
 
 
 
Cost of revenues
16,804

 
19,306

Selling and marketing
8,510

 
8,486

Research and development
4,901

 
5,869

General and administrative
7,854

 
8,676

Restructuring costs
859

 

Total costs and expenses
38,928

 
42,337

Gain on pooled patents agreement

 
21,000

Operating (loss) income
(11,358
)
 
16,468

Interest expense
(2,057
)
 
(1,994
)
Interest income
38

 
11

Other income (expense), net
23

 
(125
)
(Loss) income before income taxes
(13,354
)
 
14,360

Income tax expense
(95
)
 
(76
)
Net (loss) income
$
(13,449
)
 
$
14,284

 
 
 
 
Net (loss) income per common share, basic
 
 
 
Net (loss) income per share
$
(0.11
)
 
$
0.12

Weighted average number of shares outstanding, basic
118,859

 
117,737

 
 
 
 
Net (loss) income per common share, diluted
 
 
 
Net (loss) income per share
$
(0.11
)
 
$
0.11

Weighted average number of shares outstanding, diluted
118,859

 
146,642


4


SEQUENOM, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands)
 
 
 
 
 
March 31, 2016
 
December 31, 2015
Assets
 
 
 
Current assets:
 
 
 
Cash, cash equivalents, and marketable securities
$
66,057

 
$
76,170

Accounts receivable, net
6,950

 
6,421

Inventories
2,994

 
2,417

Other current assets and prepaid expenses
2,960

 
2,943

Total current assets
78,961

 
87,951

Property, equipment, and leasehold improvements, net
7,651

 
10,059

Other assets
18,004

 
18,718

Total assets
$
104,616

 
$
116,728

 
 
 
 
Liabilities and stockholders' deficit
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
7,078

 
$
5,234

Accrued expenses
12,523

 
15,368

Long-term debt and obligations, current portion
311

 
316

Other current liabilities
578

 
589

Total current liabilities
20,490

 
21,507

Long-term liabilities
134,054

 
133,619

Total stockholders' deficit
(49,928
)
 
(38,398
)
Total liabilities and stockholders' deficit
$
104,616

 
$
116,728


5


SEQUENOM, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 
 
 
Three Months Ended
 
March 31, 2016
 
March 31, 2015
Operating activities
 
 
 
Net (loss) income
$
(13,449
)
 
$
14,284

Adjustments to reconcile net (loss) income to net cash used in operating activities:
 
 
 
Share-based compensation
1,694

 
1,542

Depreciation and amortization
2,175

 
2,892

Other non-cash items
343

 
236

Gain on pooled patents agreement

 
(21,000
)
Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(529
)
 
1,468

Inventories
(148
)
 
1,737

Prepaid expenses and other assets
761

 
578

Accounts payable and accrued expenses
(1,066
)
 
(7,715
)
Other liabilities
146

 
(1,220
)
Net cash used in operating activities
(10,073
)
 
(7,198
)
 
 
 
 
Investing activities
 
 
 
Purchases of property, equipment and leasehold improvements
(200
)
 
(289
)
Purchases of marketable securities
(9,967
)
 
(10,007
)
Maturities and sales of marketable securities
15,009

 
10,052

Proceeds from pooled patents agreement

 
6,000

Net cash provided by investing activities
4,842

 
5,756

 
 
 
 
Financing activities
 
 
 
Payments on term loan and capital lease obligations
(87
)
 
(1,909
)
Proceeds from common stock issued under employee stock plans
223

 
177

Net cash provided by (used in) financing activities
136

 
(1,732
)
Effect of exchange rate changes on cash and cash equivalents

 
(45
)
Net decrease in cash and cash equivalents
(5,095
)
 
(3,219
)
Cash and cash equivalents at beginning of period
50,344

 
63,309

Cash and cash equivalents at end of period
$
45,249

 
$
60,090


6


SEQUENOM, INC.
RECONCILIATION OF CASH BURN
(Unaudited)
(In thousands)
 
 
 
Three Months Ended
 
March 31, 2016
 
March 31, 2015
Cash Burn:
 
 
 
Net cash used in operating activities
$
10,073

 
$
7,198

Purchases of property, equipment and leasehold improvements
200

 
289

Payments on term loan and capital lease obligations
87

 
1,909

Cash burn (1)
$
10,360

 
$
9,396

 
 
 
 
(1) See accompanying Non-GAAP Financial Measures section for description of adjustments.

7


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings